Investor Relations

About Company

ImmunityBio, Inc. and NantKwest, Inc. merged on March 9, 2021 to create a leading late-stage, cell therapy and immunotherapy company focused on oncology and infectious diseases. The combined company is called ImmunityBio, Inc. (NASDAQ: IBRX).

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent

Jul 27, 2021

ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19

Jul 14, 2021

ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients

Jun 28, 2021

FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer

Jun 15, 2021

Events

Contact Information

IR Contact

ImmunityBio Investor Relations

Phone: 1-844-696-5235, Option 5
Email

Transfer Agent & Stockholder Services

American Stock Transfer & Trust Company, LLC

AST Shareholder Services Call Center
Toll Free: 800.937.5449
Local & International: 718-921-8124
Hours: 8 a.m. – 8 p.m. ET Monday-Friday

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
Email
Website